Antibody | US EUA date | Approved | Pause to use | Manufacturer | References |
---|---|---|---|---|---|
Bamlanivimab | 11/09/2020 | ā | U.S. (04/16/2021) | Eli Lily and Company | |
REGEN-COV (Casirivimabā+āImdevimab) | 11/21/2020 | EU, UK, Japan | U.S. (01/24/2022) | Regeneron pharmaceuticals | |
Bamlanivimabā+āEtesevimab | 02/09/2021 | ā | U.S. (01/24/2022) | Eli Lily and Company | |
Xevudy (Sotrovimab) | 05/26/2021 | EU, UK | U.S. (03/30/2022) | GlaxoSmithKline plc and Vir Biotechnology, Inc | [196] |
Evusheld (Cilgavimabā+āTixagevimab) | 12/02/2021 | EU, UK | ā | AstraZeneca | [204] |
Bebtelovimab | 02/11/2022 | ā | ā | Eli Lily and Company | [242] |
Regkirona (Regdanvimab) | ā | EU, South Korea | ā | Celltrion HealthCare | [243] |